20n Bio is a VC-backed startup dedicated to discovering cyclic peptides for therapeutic use. 20n Bio's mission is to address unmet medical needs by leveraging high-throughput screening and chemical optimization to develop peptide drugs across various therapeutic areas. 20n Bio has developed a proprietary discovery platform capable of screening libraries containing trillions of peptides at once, offering unparalleled potential for de novo discovery of cyclic peptide drugs.
